Nucleus
Transcription factors
Small-molecule inhibitors against PBX1, a master regulator that keeps cancer stem cells in their resistant state.
Department of Pathology · Taipei Medical University
Cancer stem cells make up only 0.1–2% of a tumor, yet they drive therapy resistance, recurrence and metastasis. We isolate them, map what keeps them alive, and build therapies to eliminate them.
01 — Research
Nucleus
Small-molecule inhibitors against PBX1, a master regulator that keeps cancer stem cells in their resistant state.
Metabolism
Targeting glutamine metabolism (GLS) and the metabolic flexibility that lets resistant cells survive treatment.
Surface
Cell therapy and acid-responsive nanoparticles that recognize and reach cancer stem cells directly.
02 — Latest publications
2026.07
Nguyen VC, Tran K, Phan DT, Pham NT, Shen YA, Chen CL, Huang TW. BMC Palliat Care. 2026 Jul 3;25(1):281.
2026.06
Nguyen VC, Cheng KC, Phan TT, Ho TL, Lin YH, Kuo LJ, Shen YA, Chen CL., Cancer Cell Int., 2026 Jun 12;26(1):289.
2026.06
Chuang, Y. C., Chiou, J. F., Wu, P. H., Shen, Y. A., Chang, W. M., Hsia, Y., Kuo, C. C., Wang, W. J., Lo, L. W. & Lee, H. L., Jun 2026, In: Materials Today Advances. 30, 100757.

03 — Principal investigator
Associate Professor, Department of Pathology & Graduate Institute of Clinical Medicine, Taipei Medical University
Trained at National Yang-Ming University and Johns Hopkins University, Dr. Shen bridges basic cancer stem cell biology and clinical translation. He holds more than 10 patents, has received nine Young Investigator Awards, and founded Enlighten Biomedicine in 2024.
04 — Life in the lab
05 — Collaborators










Join us
Postdocs, PhD and master's students, research assistants and interns.